Objective: To determine the frequency of common chromosomal aberrations in local population of idiopathic acquired aplastic anemia at the time of diagnosis, using G-banding cytogenetic analysis. Patients and Methods: This cross sectional study was conducted in Department of Haematology, Pakistan Institute of Medical Sciences, and Islamabad and Department of Genetics, Children Hospital, Lahore from June 2015 to July 2017. Sample size was calculated using WHO sample size calculator. A total of sixty cases of peripheral blood pancytopenia having clinical suspicion of acquired aplastic anemia and diagnosed on bone marrow examination with aplastic anemia were included in the study. Bone marrow or peripheral blood samples were also processed for cytogenetics by G-banding and karyotyping according to International System for Human Cytogenetic Nomenclature (ISCN) to determine frequency of chromosomal abnormalities in the patients of acquired aplastic anaemia. Results: Sixty cases diagnosed to have acquired aplastic anaemia using bone marrow examination as gold standard were included in the study based on inclusion criteria. Forty-five out of 60 patients (75%) had successful karyotyping whereas 15 out of 60 patients (25%) had inconclusive cytogenetics due to culture failure, inadequate metaphase cells and contamination. G-banding revealed normal karyotyping in 40 out of 45 patients (88.9%) while 5 out of 45 patients (11.1%) were found to have abnormal karyotyping. Chromosomal abnormalities revealed by abnormal karyotyping included three numerical abnormalities i.e. monosomy 7, trisomy 8, trisomy 14 and two structural abnormalities i.e. deletion of 11q, deletion of 13q. The frequency of chromosomal abnormalities in patients with acquired aplastic anaemia in this study was found to be 11.1%. Conclusion: Cytogenetic analysis may be beneficial in differentiating acquired AA from other haemopoietic disorders of bone marrow failure, which may be missed, based on cell morphology alone. It also guides in deciding appropriate mode of treatment earlier and predicting prognosis of the disease.
I n t r o d u c t i o n
Aplastic anaemia is an immune mediated haemopoietic stem cell disorder characterized by pancytopenia with a hypocellular bone marrow in the absence of abnormal infiltrate and no increase in bone marrow reticulin. 1 Aplastic anemia is considered if at least two of the following defining criteria are fulfilled that includes haemoglobin level less than 10g/dl, neutrophil count less than 1.5 x 10 9 /L, platelet count less than 50 x 10 9 /L and bone marrow cellularity less than 25% or 25 to 50% with less than 30% residual haemopoietic cells. 2 Disease severity of aplastic anemia is based on the criteria given by Camitta et al. in 1975 . 3 According to these criteria the severity of aplastic anemia is graded into very severe aplastic anaemia (VSAA), severe aplastic anemia (SAA) and non-severe aplastic anemia (NSAA). Severity of aplastic anaemia according Camitta criteria is based on blood cell counts and bone marrow cellularity. 4 Grading of disease is significant in management decisions but has less prognostic value in terms of response to immunosuppressive therapy. 5 Incidence of aplastic anaemia in West is around 2 per million populations in a year, that is twofold higher (3 to 4 per million population) in Asia. 6 Aplastic anaemia can be congenital or acquired. 7 Presence of somatic abnormalities and characteristic sensitivity of haemopoietic cells to chromosomal breakage on exposure to clastogenic agents such as diepoxybutane (DEB) and mitomycin c (MMC) is suggestive of congenital aplastic anemia. 8 Some cases of congenital aplastic anemia may lack the characteristic phenotypic abnormalities. 9 Constitutional mutations result in increased genomic instability and reduced cell survival in congenital aplastic anaemia that leads to increased chromosomal DNA damage by DNA crosslinking agents due to aberration in BRCA pathway. 10 BRCA gene (a tumor suppressor gene) is involved in DNA damage response pathway; cells lacking BRCA protein are susceptible to chromosomal breakage after exposure to DEB or MMC. 11 Acquired aplastic anaemia is associated with various etiological factors that include different drugs, chemicals, ionizing radiations, pregnancy, autoimmune diseases, graft versus host disease and viral infections. 12 No definitive causative factor is found in majority of the cases of acquired aplastic anaemia. 13 Monosomy 7 is associated with a high risk to develop haematological malignancies (MDS or AML) and has poor response to immunosuppressive therapy (IST) with poor prognosis. 16 In contrast, trisomy 8 is associated with good response to IST and has better prognosis. 17 Cytogenetic analysis is attempted to detect cytogenetic abnormalities related with acquired aplastic anaemia, although it is difficult to perform because of inability to obtain sufficient metaphase cells for chromosomal analysis in a hypocellular bone marrow. 18 In such situation, molecular cytogenetics by fluorescent in situ hybridization (FISH) can be attempted which is limited to few centers only and has a higher cost constraint. 19 Clinical significance of cytogenetic abnormalities may also be that hypo plastic MDS or hypo plastic AML may present as aplastic anaemia and it can be difficult to distinguish two conditions on basis of morphology alone, treatment option and response to treatment is also different in such condition. 20 Cytogenetic analysis is limited to a few centers in Pakistan. Incidence of aplastic anemia is relatively more common in Southeast Asian countries. No study has been conducted before, to find association of cytogenetic abnormalities with acquired AA in Pakistan. The objective of this study was to determine frequency of common chromosomal aberrations among the patients of idiopathic acquired aplastic anemia in local population at the time of diagnosis by G-banding cytogenetic analysis. Inconclusive cytogenetics can be due to cell culture failure, inadequate metaphase cells or contamination. Gbanding revealed normal cytogenetics results in 40 out of 45 patients (89.9%) among those 24 were male and 16 were female, while five out of 45 patients (11.1%) had cytogenetic abnormalities among those two were male and three were female, table 2. Majority of the patients of acquired aplastic anemia (n=40) included in this study had normal cytogenetics. In total 44 patients had NSAA, 13 SAA and 3 patients had VSAA (Table 1) . Among five patients with chromosomal abnormalities, three patients had severe aplastic anaemia (SAA) while two patients were diagnosed to have non-severe aplastic anaemia (NSAA). Chromosomal abnormalities revealed by Gbanding in five patients of acquired aplastic anemia were numerical and structural. Three out of five patients had numerical chromosomal abnormalities among those one was male and two were female having monosomy 7, trisomy 8 and trisomy 14 respectively whereas two out of five patients had structural chromosomal abnormalities among those one was male and one was female having deletion of 11q and deletion of 13q respectively. All five patients of acquired aplastic anemia found to have abnormal cytogenetics in this study were in age group of 1 -18 years. The frequency breakup of chromosomal abnormalities is depicted in table 3.
P a t i e n t s a n d M e t h o d s

D i s c u s s i o n
Aplastic anaemia is haematological disorder of bone marrow failure characterized by T cell mediated destruction of haemopoietic cells. 22 In the current study, cytogenetic abnormalities were observed in 11.1% patients of acquired aplastic anemia. Trisomy was the commonest numerical cytogenetic abnormality seen in two patients followed by monosomy in one patient. Deletions were the structural cytogenetic abnormalities found in two patients. Clinical and haematological profile of the patients with abnormal cytogenetics were similar to those with normal cytogenetics. 23 Some of these characteristic cytogenetic abnormalities are also seen in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), however the morphological diagnosis was consistent with aplastic anemia. It may be difficult to distinguish two conditions on the basis of cell morphology alone therefore in this situation abnormal karyotype may suggest diagnosis of hypoplastic MDS or hypoplastic AML. Cytogenetic analysis can play a significant role in management of patients with cytogenetic interpretation, which can reduce risk of misdiagnosing hypoplastic MDS and hypoplastic AML as aplastic anemia, monosomy and trisomy are mostly seen in aplastic anemia, deletions favor diagnosis of MDS whereas translocations and inversions are commonly found in AML. Cytogenetic analysis in this way may be most beneficial in differentiating aplastic anemia from other haemopoietic disorders of bone marrow hypoplasia/aplasia, therefore guides in suggesting appropriate mode of treatment that helps in avoiding possibility of mistreating the patients. Some authorities exclude diagnosis of aplastic anaemia in patients with abnormal cytogenetics regardless of bone marrow morphology, however in some research centers patients with abnormal cytogenetics are diagnosed as aplastic anemia on morphological grounds. 24 Response to therapy and survival in patients of aplastic anaemia with normal and abnormal cytogenetics was also compared in some studies. 25 Patients without cytogenetic abnormalities have good response to immunosuppressive therapy (IST) and better survival therefore cytogenetic analysis helps in predicting prognosis of aplastic anemia. Patients with persistent cytogenetic abnormalities after treatment are at higher risk of developing haematological malignancies (AML or MDS). Patients of MDS presents with clinical manifestations of bone marrow failure which are related to anaemia, neutropenia and thrombocytopenia. 26 Immunosuppressive therapy (IST) improves pancytopenia but response is relatively poor in patients of MDS. 27 In few patients, acquired aplastic anaemia may develop into acute leukemia. 28 Patients of AML presents with clinical features of bone marrow failure and organ infiltration by leukemic cells. Chemotherapy regimens have limited role in treating patients with AML. 29 In this study cytogenetic abnormalities in patients of acquired aplastic anemia were found to be 11.1% in our region. These findings are compatible with the study conducted by Vineeta Gupta et al. at Institute of Medical Sciences, Banaras University, India who found cytogenetic abnormalities to be 11.9% in patients of AA. 30 Similar figures are reported in various other studies, demonstrating chromosomal abnormalities in acquired AA. 31 Some patients with acquired aplastic anaemia are at higher risk of evolving into MDS. It is sometimes difficult to distinguish between the two conditions. 32 Prognosis of the patients with acquired aplastic has improved with better supportive care of anaemia, infections and bleeding. 33 Estimated 10-years survival is 68% in patients receiving IST and 73% in patients with HSCT. Mode of treatment in patients with aplastic anaemia depends on age of the patients, children with HLA matched sibling donor are preferably treated with HSCT whereas adults without HLA matched sibling donor are generally treated with IST along with supportive therapy. Approximately 25% patients of AA have inadequate response to therapy. 34 HSCT is the curative treatment option, however may be at additional risk of developing graft versus host disease (GVHD) and potential for graft rejection. 35 .
C o n c l u s i o n
Cytogenetic analysis may be beneficial in differentiating acquired AA from other haemopoietic disorders of bone marrow failure, which may be missed, based on cell morphology alone. It also guides in deciding appropriate mode of treatment earlier and predicting prognosis of the disease.
